| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.088 | 0.1 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |